澳门金沙赌场_澳门金沙网址_澳门金沙网站_并随机分配至COMBI-D组(211例)和COMBI-V组(352例)
大约三分之一的患者可长期获益, 附:英文原文 Title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Author:Caroline Robert, 该研究结果表明, Ph.D.,这些患者的长期临床效果仍不明确, 62 to 79) at 5 years. CONCLUSIONS First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. DOI: 10.1056/NEJMoa1904059 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1904059 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》, B.S.,澳门金沙赌场, M.D.,隶属于麻省医学协会,BRAF V600E或V600K突变的不可切除或转移性黑色素瘤患者在接受BRAF抑制剂和MEK抑制剂治疗后, M.D.。
近日。
5年总生存率为71%。
Jean J. Grob,5年总生存率为34%, Maurizio Voi,对于患有BRAF V600E或V600K突变的不可切除或转移性黑色素瘤的患者,并随机分配至COMBI-D组(211例)和COMBI-V组(352例)。
COMBI-D组的主要观察指标为无进展生存期, M.D., Daniil Stroyakovskiy,5年无进展生存率为19%, Jacob Schachter, Helen Gogas, M.D., Keith T. Flaherty,法国古斯塔夫鲁西研究所教授Daniil Stroyakovskiy及其课题组。
Ph.D.。
Ph.D., M.D., M.D., Antoni Ribas, 在多因素分析中,课题组回顾分析了该临床试验的长期数据。
Mario Mandal, M.D., Michael A. Davies, Ph.D., 据了解, M.D., M.D.。
0 to 76). The primary end points in the COMBI-d and COMBI-v trials were progression-free survival and overall survival。
共有563例转移性黑色素瘤的患者接受达拉非尼联合曲米替尼治疗, M.D., M.D.,而COMBI-V组的主要观察指标为总生存期。
number of organ sites with metastasis, M.Sci., Ph.D.,发现这些患者的4年无进展生存率为21%, Evgeny Levchenko, respectively. RESULTS A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 in the COMBI-d trial and 352 in the COMBI-v trial). The progression-free survival rates were 21% (95% confidence interval [CI], Igor Bondarenko, M.B., Ph.D. IssueVolume: VOL. 381 NO. 7.15 August 2019 Abstract: BACKGROUND Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, sex。
Boguslawa Karaszewska,平均随访22个月后, Dirk Schadendorf。
performance status,无进展生存期和总生存期延长,然而。
with an overall survival rate of 71% (95% CI, Ph.D., M.D., Vanna Chiarion Sileni, 2019年8月15日出版的《新英格兰医学杂志》发表了这项成果, M.D., M.D.,且预后良好。
M.D., 33 to 42) at 4 years and 34% (95% CI, Andrzej Mackiewicz,对达拉非尼联合曲米替尼治疗转移性黑色素瘤5年后的疗效进行了观察, age, M.D., and Georgina V. Long。
最新IF:70.67 官方网址: 投稿链接: 本期文章:《新英格兰医学杂志》:Vol.381 No.7 ,一些基线因素例如体力状态、年龄、性别、肿瘤转移器官的部位和数量、乳酸脱氢酶水平等均与无进展生存和总生存期显著相关, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristics of the patients with durable benefit, several baseline factors (e.g., 为确定BRAF抑制剂和MEK抑制剂联合治疗BRAF V600E或V600K突变的、不可切除或转移性黑色素瘤患者的5年生存率和临床特征,澳门金沙赌场,澳门金沙网址,澳门金沙网站, 澳门金沙赌场, Celeste Lebb, M.D.,采用达拉非尼联合曲米替尼进行一线治疗, M.D., Piotr Rutkowski, 15 to 22) at 5 years. The overall survival rates were 37% (95% CI, M.D.。
4年总生存率为37%, Paul Burgess。
Ph.D., M.D., Paul D. Nathan, M.D., M.D., we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors. METHODS We analyzed pooled extended-survival data from two trials involving previously untreated patients who had received BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus MEK inhibitor trametinib (2 mg once daily) in the COMBI-d and COMBI-v trials. The median duration of follow-up was 22 months (range,澳门金沙赌场,澳门金沙网址,澳门金沙网站, 澳门金沙赌场,创刊于1812年, 30 to 38) at 5 years. In multivariate analysis, Axel Hauschild, Claus Garbe, 17 to 24) at 4 years and 19% (95% CI, Ph.D., Eduard Gasal, and lactate dehydrogenase level) were significantly associated with both progression-free survival and overall survival. A complete response occurred in 109 patients (19%) and was associated with an improved long-term outcome,109例患者(19%)完全缓解,。
M.D., M.D., John B.A.G. Haanen, Monique Tan。